,31 As luminal B tumours are to a large extent characterised by a negative PR status and a high-risk MammaPrint score, these findings support our present results on the lack of efficacy of extended aromatase inhibition in patients with luminal B-like tumours. The gene discussed is CYP19A1; the disease is neoplasm.